Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies Published September 2019 Citation Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR. . ESMO Annual Congress. . https://www.annalsofoncology.org/article/S0923-7534(19)59501-1/pdf Authors:Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR Sources:ESMO Annual Congress Share Posted inPublicationsComparative effectivenessMelanoma More publicationsASCO Annual MeetingMay 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerGanti AK, Snider J, Yan J, et al.Publication summaryPublicationsComparative effectivenessSmall cell lung cancerASCO Annual MeetingMay 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumabOrcutt X, Nimgaonkar V, Sun L, et al.Publication summaryPublicationsMachine learningComparative effectivenessNon-small cell lung cancerArtificial intelligenceASCO Annual MeetingMay 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumabOrcutt X, Nimgaonkar V, Sun L, et al.Publication summaryPublicationsMachine learningComparative effectivenessHead and neck cancerArtificial intelligence